Premium
Interindividual Variation in the Pharmacokinetics of Δ9‐Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9
Author(s) -
SachseSeeboth C,
Pfeil J,
Sehrt D,
Meineke I,
Tzvetkov M,
Bruns E,
Poser W,
Vormfelde SV,
Brockmöller J
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2008.213
Subject(s) - cyp2c9 , pharmacokinetics , pharmacology , clinical pharmacology , tetrahydrocannabinol , pharmacogenetics , medicine , sedation , delta 9 tetrahydrocannabinol , genotype , biology , cannabinoid , genetics , gene , cytochrome p450 , receptor , metabolism
The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered Δ9‐tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9*2 allele status. However, the median area under the curve of THC was threefold higher and that of 11‐nor‐9‐carboxy‐9‐tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes. CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC. Clinical Pharmacology & Therapeutics (2009); 85 , 3, 273–276 doi: 10.1038/clpt.2008.213